ESCRS Registration. “Early bird” registration is now open for the 43rd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS). The conference will run from Friday 12 to Tuesday 16 September 2025 in Copenhagen, Denmark, with more than 6,000 ophthalmology experts from over 120 different countries gathering to discuss the latest research on cataract surgery, glaucoma, corneal transplantation, corrective eye surgery, and more. This year, the programme includes everything from instructional and didactic courses, to clinical research symposiums, wet/dry labs, exhibitions, and poster presentations. Link
DREAM big. Last week, Intalight, a global ophthalmic company founded in Silicon Valley that is focused on advancing OCT/OCTA imaging technologies, announced that it has received CE mark for its DREAM OCT™ platform. The DREAM (Deep imaging depth, Rapid sweeping speed, Extensive scan range, Accurate results, and Multimodal imaging capabilities) platform uses ultra-wide swept-source technology to deliver a 130° OCTA image. “This is such exciting news for Intalight that there’s no more waiting in Europe, and we look forward to being able to provide this innovative solution in the US,” says Intalight’s Chief Commercial Officer, Joe Garibaldi. “We look forward to continuing to grow our prestigious network of global institutions and ophthalmologists with our recent CE approval and eventually our FDA approval.” Link
Pediatric uveitis and early-onset AD links. A large multicenter cohort study has investigated the link between early-onset atopic dermatitis (AD) and the risk of developing pediatric uveitis. Using data from over 114,000 children with AD and matched controls, the Chi Mei Medical Center, Taiwan, team of researchers found that children with early-onset AD had a significantly higher risk of pediatric uveitis, particularly iridocyclitis, independent of autoimmune conditions or use of the AD treatment dupilumab. The risk was especially elevated among those with severe AD, who had more than three times the risk of developing uveitis compared to those with nonsevere AD. These findings suggest that early ophthalmologic monitoring may be beneficial for children diagnosed with early-onset AD to detect and manage potential ocular complications. Link
HbA1c peak for DR risk. A cross-sectional study published in BMC Ophthalmology has investigated the relationship between HbA1c levels and diabetic retinopathy (DR) in 2,001 patients with type 2 diabetes in southern Taiwan. The researchers, based at Gansu Provincial Hospital, China, found a significant inverted U-shaped association, where the risk of DR increased with rising HbA1c levels up to a peak at 9.4 percent, after which the risk began to decline. This suggests that while moderate increases in HbA1c are linked to higher DR risk, very high HbA1c levels may not continue to elevate that risk – possibly due to metabolic memory or saturation of retinal damage. The findings emphasize the importance of personalized glycemic management and targeted screening strategies to prevent DR, especially around the critical HbA1c threshold. Link
